BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 27499020)

  • 1. Phosphoproteome Integration Reveals Patient-Specific Networks in Prostate Cancer.
    Drake JM; Paull EO; Graham NA; Lee JK; Smith BA; Titz B; Stoyanova T; Faltermeier CM; Uzunangelov V; Carlin DE; Fleming DT; Wong CK; Newton Y; Sudha S; Vashisht AA; Huang J; Wohlschlegel JA; Graeber TG; Witte ON; Stuart JM
    Cell; 2016 Aug; 166(4):1041-1054. PubMed ID: 27499020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets.
    Drake JM; Graham NA; Lee JK; Stoyanova T; Faltermeier CM; Sud S; Titz B; Huang J; Pienta KJ; Graeber TG; Witte ON
    Proc Natl Acad Sci U S A; 2013 Dec; 110(49):E4762-9. PubMed ID: 24248375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
    Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
    Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen receptor co-regulatory networks in castration-resistant prostate cancer.
    Sung YY; Cheung E
    Endocr Relat Cancer; 2014 Feb; 21(1):R1-R11. PubMed ID: 24152433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Personalization of prostate cancer therapy through phosphoproteomics.
    Yang W; Freeman MR; Kyprianou N
    Nat Rev Urol; 2018 Aug; 15(8):483-497. PubMed ID: 29752463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer.
    Stoyanova T; Riedinger M; Lin S; Faltermeier CM; Smith BA; Zhang KX; Going CC; Goldstein AS; Lee JK; Drake JM; Rice MA; Hsu EC; Nowroozizadeh B; Castor B; Orellana SY; Blum SM; Cheng D; Pienta KJ; Reiter RE; Pitteri SJ; Huang J; Witte ON
    Proc Natl Acad Sci U S A; 2016 Oct; 113(42):E6457-E6466. PubMed ID: 27694579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlating phosphoproteomic signaling with castration resistant prostate cancer survival through regression analysis.
    Lescarbeau R; Kaplan DL
    Mol Biosyst; 2014 Mar; 10(3):605-12. PubMed ID: 24413303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphoproteomics of extracellular vesicles integrated with multiomics analysis reveals novel kinase networks for lung cancer.
    Qiao Z; Kong Y; Zhang Y; Qian L; Wang Z; Guan X; Lu H; Xiao H
    Mol Carcinog; 2022 Dec; 61(12):1116-1127. PubMed ID: 36148632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
    Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
    Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer.
    Roudier MP; Winters BR; Coleman I; Lam HM; Zhang X; Coleman R; Chéry L; True LD; Higano CS; Montgomery B; Lange PH; Snyder LA; Srivastava S; Corey E; Vessella RL; Nelson PS; Üren A; Morrissey C
    Prostate; 2016 Jun; 76(9):810-22. PubMed ID: 26990456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcriptome Sequencing Reveals PCAT5 as a Novel ERG-Regulated Long Noncoding RNA in Prostate Cancer.
    Ylipää A; Kivinummi K; Kohvakka A; Annala M; Latonen L; Scaravilli M; Kartasalo K; Leppänen SP; Karakurt S; Seppälä J; Yli-Harja O; Tammela TL; Zhang W; Visakorpi T; Nykter M
    Cancer Res; 2015 Oct; 75(19):4026-31. PubMed ID: 26282172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet-Synthesized Testosterone in Men with Prostate Cancer Induces Androgen Receptor Signaling.
    Zaslavsky AB; Gloeckner-Kalousek A; Adams M; Putluri N; Venghatakrishnan H; Li H; Morgan TM; Feng FY; Tewari M; Sreekumar A; Palapattu GS
    Neoplasia; 2015 Jun; 17(6):490-6. PubMed ID: 26152357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Molecular targeting drug of kinase inhibitors for castration resistant prostate cancer].
    Kosaka T; Oya M
    Nihon Rinsho; 2014 Dec; 72(12):2186-92. PubMed ID: 25518356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
    Martin SK; Kyprianou N
    Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening key microRNAs for castration-resistant prostate cancer based on miRNA/mRNA functional synergistic network.
    Zhu J; Wang S; Zhang W; Qiu J; Shan Y; Yang D; Shen B
    Oncotarget; 2015 Dec; 6(41):43819-30. PubMed ID: 26540468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipocalin 2 over-expression facilitates progress of castration-resistant prostate cancer via improving androgen receptor transcriptional activity.
    Ding G; Wang J; Feng C; Jiang H; Xu J; Ding Q
    Oncotarget; 2016 Sep; 7(39):64309-64317. PubMed ID: 27602760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of the transcriptional coactivator FHL2 licenses activation of the androgen receptor in castrate-resistant prostate cancer.
    McGrath MJ; Binge LC; Sriratana A; Wang H; Robinson PA; Pook D; Fedele CG; Brown S; Dyson JM; Cottle DL; Cowling BS; Niranjan B; Risbridger GP; Mitchell CA
    Cancer Res; 2013 Aug; 73(16):5066-79. PubMed ID: 23801747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated network model provides new insights into castration-resistant prostate cancer.
    Hu Y; Gu Y; Wang H; Huang Y; Zou YM
    Sci Rep; 2015 Nov; 5():17280. PubMed ID: 26603105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Basis of Drug Resistance and Insights for New Treatment Approaches in mCRPC.
    Giacinti S; Poti G; Roberto M; Macrini S; Bassanelli M; DI Pietro F; Aschelter AM; Ceribelli A; Ruggeri EM; Marchetti P
    Anticancer Res; 2018 Nov; 38(11):6029-6039. PubMed ID: 30396917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrative genomic, transcriptomic, and RNAi analysis indicates a potential oncogenic role for FAM110B in castration-resistant prostate cancer.
    Vainio P; Wolf M; Edgren H; He T; Kohonen P; Mpindi JP; Smit F; Verhaegh G; Schalken J; Perälä M; Iljin K; Kallioniemi O
    Prostate; 2012 May; 72(7):789-802. PubMed ID: 21919029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.